Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Omnicell Q3 2026 Results: Net Income $11M, Up 102.2% YoY

Omnicell reported total revenues of $929.9 million for the nine months ended September 30, 2026, a significant increase from $870.9 million in the prior year period. Net income for the same period rose sharply to $46.7 million compared to $4.1 million in 2025, driven by improved gross margins and controlled operating expenses.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue307.9310.6
Gross profit137.8134.5
Profit before tax15.89.7
Net income11.05.5
EPS (diluted, $ a share)$0.24$0.12

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+102.2%
Revenue, year on year-0.9%
Gross margin44.8%
Operating margin4.9%
Source

10-Q filed with the SEC, NASDAQ: OMCL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Omnicell, Inc.: key numbers

Share price
$35.44Close, Nov 16
Market cap
$1.63B
Shares outstanding
46MLatest SEC cover page
Sector
Technology
Industry
Electronic ComputersSIC 3571

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Omnicell, Inc.

All →
6:37 AM ET 8-K
Financial Results

Omnicell Financial Results

Omnicell reported third quarter 2026 financial results with revenue of $308 million and GAAP net income of $11 million, both exceeding the high end of previous guidance. The company highlighted strong momentum for its next-generation Titan XT and OmniSphere platforms as healthcare providers prioritize medication management efficiency.

“We delivered solid third quarter results and continued to execute against our strategic priorities. We believe our performance reflects the discipline we have built into the business throughout the year, combined with continued customer interest in solutions that are designed to improve efficiency, safety, and workforce productivity across medication management.”

Randall A. Lipps, chairman, chief executive officer, and founder of Omnicell

“At the same time, we continue to see strong momentum with our next-generation platform, backed by a growing pipeline. Customers are validating the potential value of combining Titan XT with OmniSphere, our cloud-native platform, intended to improve productivity, efficiency, and workflow reliability.”

Randall A. Lipps, chairman, chief executive officer, and founder of Omnicell

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.